Enrolling by invitationNCT00068003
Harvesting Cells for Experimental Cancer Treatments
Studying Bronchial neuroendocrine tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Steven A Rosenberg, M.D., MDNational Cancer Institute (NCI)
- Intervention
- Anti-CD19 CAR PBL(drug)
- Enrollment
- 7000 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2003
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00068003 on ClinicalTrials.govOther trials for Bronchial neuroendocrine tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07174583A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerIDEAYA Biosciences
- RECRUITINGNANCT07555210Pilot Study of Bone Mineral Density Changes During Anti-PD-1 ImmunotherapyJessica Mezzanotte Sharpe
- RECRUITINGPHASE1, PHASE2NCT05636618Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine TumorsPerspective Therapeutics
- RECRUITINGPHASE2NCT04665739Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT05522660Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung CancerETOP IBCSG Partners Foundation
- RECRUITINGPHASE1NCT04429087A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Boehringer Ingelheim
- ACTIVE NOT RECRUITINGPHASE1NCT02589522Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsNational Cancer Institute (NCI)